Beone Medicines secured an exclusive worldwide option to develop Huahui Health’s trispecific antibody HH-160 in a deal potentially worth more than $2 billion. The arrangement gives Beone global rights contingent on further development milestones for the cancer immunotherapy candidate. The transaction adds to ongoing competition for antibody-based oncology engines that can differentiate by binding architecture and disease targeting. The key next variable is whether HH-160’s clinical data can justify the option value through later-stage checkpoints.